RT Journal Article
T1 Colistin resistance screening by 3 μg/ml colistin agar in Carbapenemase-producing Enterobacterales.
A1 Soria-Segarra, Claudia
A1 Soria-Segarra, Carmen
A1 Andrade-Soriano, Michelle
A1 Quezada, Tamara Nuñez
A1 Gestal, Monica C
A1 Gutierrez-Fernandez, Jose
K1 Carbapenemase-producing Enterobacterales
K1 broth microdilution
K1 colistin dilution agar
K1 colistin resistance
K1 surveillance
AB In low- and middle-income countries, the use of colistin in therapeutic regimens is common, to treat infections produced for Carbapenemase-producing Enterobacterales (CPE) due to limited access to the recently discovered-approved antibiotics. Furthermore, the technical limitations to perform colistin susceptibility tests make it difficult to assess the suitability of this treatment for each patient, as well as to monitor the rates of resistance. In the present study, we describe the use of agar dilution using a unique colistin concentration of 3 μg/ml to discriminate isolates with colistin resistance in CPE obtained from clinical samples. Clinical Laboratory Standards Institute (CLSI) colistin broth microdilution method and dilution agar with a colistin concentration of 3 μg/ml were performed in 168 isolates of CPE obtained from clinical samples in Guayaquil, Ecuador. Broth microdilution was considered our gold standard using CLSI breakpoints as reference (≤2 μg/ml intermediate and ≥4 μg/ml resistant). Categorical agreement was defined as obtaining a reading within the same category with both methodologies. Isolates obtained from respiratory samples were the most prevalent (26.19%; n = 44). Klebsiella pneumoniae was the predominant specie (94.04%; n = 158). KPC-like carbapenemase was present in all the isolates, and interestingly, colistin resistance was not mediated by MCR-1 production. Categorical agreement between both methods resulted in 97.02%. We propose the use of dilution agar with a colistin concentration of 3 μg/ml, as a valid method for screening colistin resistance in low- and middle-income countries to monitor resistance and to perform epidemiological studies.
PB John Wiley & Sons, Inc.
YR 2022
FD 2022-07-23
LK http://hdl.handle.net/10668/22162
UL http://hdl.handle.net/10668/22162
LA en
NO Soria-Segarra C, Soria-Segarra C, Andrade-Soriano M, Quezada TN, Gestal MC, Gutierrez-Fernandez J. Colistin resistance screening by 3 μg/ml colistin agar in Carbapenemase-producing Enterobacterales. J Clin Lab Anal. 2022 Sep;36(9):e24639.
NO his work was conducted under the collaborative research projecton “Estudio de morbi-mortalidad por Enterobacterias productorasde carbapenemasas resistentes a colistina en Guayaquil, durante losaños 2019-2020” by Universidad Catolica Santiago de Guayaquil(grant number SIU#510-298) and grant from Sosecali C. LTDA (grantnumber 001-020)
DS RISalud
RD Apr 7, 2025